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Abstract
Purpose: Postoperative radiation therapy (RT) is commonly used for World Health Organization grade II-III intracranial ependymoma.
Clinicians generally aim to begin RT ≤5 weeks after surgery, but postoperative recovery and need for second look surgery can delay the
initiation of adjuvant therapy. On ACNS 0831, patients were required to enroll ≤8 weeks after initial surgery and begin adjuvant therapy
within 3 weeks after enrollment. The purpose of this study was to determine the optimal timing of RT after surgery.
Methods and Materials: The National Cancer Database was queried for patients (aged 1-39 years) with localized World Health
Organization grade II-III intracranial ependymoma treated with surgery and postoperative RT. Overall survival (OS) curves were
plotted based on RT timing (≤5 weeks, 5-8 weeks, and >8 weeks after surgery) and were compared by log-rank test. Factors
associated with OS were identified by multivariate analysis. After 2009, complete data were available on whether patients underwent
gross total resection or subtotal resection. Planned subset analysis was performed to examine the effect of RT timing on OS in patients
with known extent of resection.
Results: In the final analytical data set of 1043 patients, no difference in 3-year OS was observed in patients who initiated RT ≤5
weeks, 5 to 8 weeks, and >8 weeks after surgery (89.8% vs 89.1% vs 88.4%; P = .796). On multivariate analysis, grade III tumors
(hazard ratio, 2.752; 95% confidence interval, 1.969-3.846, P < .001) and subtotal resection (hazard ratio, 2.253; 95% confidence
interval, 1.405-3.611, P < .001) were significantly associated with reduced OS. Timing of RT, total RT dose, age, and other factors
were not significant. These findings were affirmed in the subset of patients treated between 2010 and 2016, when extent of resection
was routinely recorded.
Conclusions: Delayed postoperative RT was not associated with inferior survival in patients with intracranial ependymoma. Delayed
RT initiation may be acceptable in patients who require longer postoperative recovery or referral to an appropriate RT center, but
should be minimized whenever practical.
© 2021 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Ependymoma is the second-most common malignant
intracranial tumor in pediatric patients, with approximately 1372 new cases diagnosed per year in the United
States.1 Pediatric ependymoma are almost exclusively
located within the brain, with two-thirds residing in the
posterior fossa. Maximal safe resection is the primary
curative treatment in all patients. Adjuvant radiation therapy (RT) is generally recommended in patients with
World Health Organization (WHO) grade II-III ependymoma after maximal safe resection.2 The role of chemotherapy is not well characterized3; however, in very
young patients, adjuvant chemotherapy may be used to
delay RT due to concerns about late adverse effects.4-6
The optimal timing between surgical resection and
adjuvant RT has been examined in medulloblastoma7,8
but not in ependymoma. Many physicians strive to begin
within 5 weeks of surgery, similar to many malignant
brain tumors. Selected patients, however, may experience
unavoidable delays to enable adequate postoperative
recovery or to facilitate referral to a high volume pediatric center. All patients in Children’s Oncology Group
ACNS 0121 and ACNS 0831 (NCT01096368) were
required to enroll within 8 weeks of initial surgery and
initiation of adjuvant therapy within 3 weeks from enrollment. Currently, there are limited data demonstrating the
effect of delayed RT on overall survival (OS).
The aim of our study was to analyze the association
between the time interval from surgical resection to adjuvant RT on OS in patients with ependymoma using the
National Cancer Database (NCDB). We hypothesized that
delayed adjuvant RT may be associated with decreased OS.

Methods and Materials
Study design and population
We analyzed deidentified patient data obtained from
the NCDB, a large hospital-based registry that captures
approximately 70% of all cancer incidence in the United
States from more than 1500 hospitals accredited by the
Commission on Cancer. The NCDB is a joint project of
the Commission on Cancer and the American College of
Surgeons. The data used in the study were derived from a
deidentified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified
and are not responsible for the analytical or statistical
methodology employed or the conclusions drawn from
these data by the investigators. After evaluation and
approval of the research design by the clinical trials
office, institutional review board approval was not
required for this study.
Patients with ependymoma between the ages of 1 and
39 years were identified in the NCDB data set using
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primary site and histology codes.1 The analytical cohort
was generated to include patients who received diagnoses
of ependymoma between 2004 and 2016, which yielded
2433 subjects. Patients were excluded if they had WHO
grade I or IV tumors, history of prior malignancy, metastatic disease, received radiation doses <50 or ≥61.5 Gy,
or had incomplete data for vital status or date of last contact. Patients were also excluded if they received only 1
treatment modality with either surgery or RT or received
RT before surgery. The final analytical cohort included
1043 patients. The selection criteria for the final data set
are illustrated in Figure 1.
Complete information on extent of surgical resection
was not included in the NCDB until 2010. A planned subgroup analysis was performed for all patients who had
complete information on extent of surgical resection,
classified as either gross total resection (GTR) or subtotal
resection (STR)/biopsy. This yielded 565 patients for this
subgroup analysis, representing all patients diagnosed
and treated from 2010 to 2016.
The primary exposure of our study was time between
initial surgery and the start of adjuvant RT, divided into 3
strata (<5 weeks, 5-8 weeks, >8 weeks). The primary
outcome was OS. Additional covariates included age (120, 21-39), race, sex, WHO grade (II, III), tumor location
(supratentorial, infratentorial), extent of surgical resection (GTR, STR), Charlson Deyo comorbidity score (0,
1, 2, or 3), insurance status (private, Medicaid/government, uninsured), distance from hospital (≤50 miles, >50
miles), year of diagnosis (2004-2006, 2007-2009, 20102012, 2013-2015), household income (stratified by quartile), and RT dose (≤54 Gy, >54 Gy).

Statistical analysis
Statistical analysis was performed using SPSS version
26.0 (SPSS Inc, Chicago, IL). Differences between categorical variables were compared using the x2 test. Survival curves were plotted using the Kaplan-Meier
product limit method and were compared using the logrank test. Multivariate proportional hazards analysis
(MVA) with backward stepwise regression was used to
identify factors associated with OS. Two-sided P values
< .05 were considered statistically significant. The proportional hazards assumption was tested for a nonzero
slope in the generalized linear model using scaled
Schoenfeld residuals. Multiple imputation methods were
used to address limitations due to missing data.

Results
Patient demographics and tumor characteristics are
presented in Table 1. Median age was 9 years (interquartile range, 3-22). Younger patients (age <21 years) and
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All NCDB Paents with Intracranial Brain Tumors (2004-2016) [n=58,614]

Inclusion:
Ependymoma histology

2433

Exclusion:
History of prior malignancy [n=66]
WHO Grade I and IV tumors [n=121]
Metastac disease [n=49]
Missing data for vital status or date of last contact
[n=157]

2040
Exclusion:
Radiaon dose <50 Gy or >61.5 Gy [n=965]
1075
Exclusion:
Paents who received one modality treatment, RT
before surgery, or addional RT [n=32]
1043
Subgroup Analysis:
Missing data for GTR/STR, which were paents treated
between 2006-2009 [n=478]
565
Figure 1

Inclusion and exclusion criteria used to select the primary analytical data set and the planned subgroup analysis.

those with grade III tumors were more likely to begin
postoperative RT earlier after initial surgery than older
patients and those with grade II tumors. All other comparisons showed no significant and/or no clear discernable difference between the groups. Median follow-up
was 4.77 years for surviving patients. At the close-out
date, 17.3% of patients had died.
In this cohort, no significant OS difference was
observed between patients who received adjuvant RT <5
weeks, 5 to 8 weeks, or >8 weeks after surgical resection,
with 3-year OS rates of 89.8%, 89.1%, and 88.4%
(P = .796), respectively. The Kaplan-Meier plots are
illustrated in Figure 2. Similarly, no significant difference
in OS was observed in the subgroup of patients treated
between 2010 and 2016 with known extent of surgical
resection (P = .802). The Kaplan-Meier curves for this
subgroup are shown in Figure 3.
On MVA, we observed no significant association
between the timing of postoperative RT and OS (Table 2).
In the complete data set, WHO grade III tumors were significantly associated with increased hazard of death (hazard ratio [HR], 2.752; 95% confidence interval [CI],
1.969-3.846, P < .001) compared with WHO grade II
tumors. STR was also associated with an increased risk
of death (HR, 2.253; 95% CI, 1.405-3.611, P <.001).

Age, sex, race, distance from hospital, household income,
insurance, tumor location, RT dose, and Charlson Deyo
score demonstrated no association with OS.
In the subgroup of patients with known extent of
resection, MVA illustrated similar findings relative to the
primary analytical cohort. WHO grade III tumors (HR,
4.296; 95% CI, 2.334-7.906, P < .001) and STR (HR,
2.267; 95% CI, 1.381-3.721, P = .001) remained significant on MVA. Postoperative RT timing and other additional variables were not associated with OS.

Discussion
We evaluated the effect of the time interval between
surgery and postoperative RT on survival in patients with
intracranial ependymoma using a large hospital-based
registry. Our study demonstrated no significant difference
in OS between patients who received early versus
delayed RT in the NCDB.
To our knowledge, no large database studies to date
have evaluated the effect of postoperative RT timing on
outcomes in ependymoma. Patteson and colleagues9
recently reported no detriment in OS or local control if
RT started within 9 weeks in a single institution study of
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Patient demographics and tumor characteristics

Patient characteristics

Time to RT <5 weeks

Total

Time to RT 5-8 weeks

Time to RT >8 weeks

No.

%

No.

%

No.

%

No.

%

Total age (years)

1043

100

334

100

363

100

346

100

1-20
21-39
Race
White
Nonwhite
Unknown
Sex
Male
Female
Charlson Deyo score
0
1
2
3
Insurance
Private
Medicaid/gov.
Uninsured
Unknown
Residential distance
to hospital (miles)
≤50 miles
>50 miles
Median income
1st quartile (Lowest)
2nd quartile
3rd quartile
4th quartile (Highest)
Unknown
Year of diagnosis
2004-2006
2007-2009
2010-2012
2013-2015
WHO grade
Grade II
Grade III
Tumor location
Infratentorial
Supratentorial
Unknown
Surgical resection
GTR
STR
Unknown
RT dose (Gy)
≤54
>54

752
291

72.1
27.9

266
68

79.6
20.4

274
89

75.5
24.5

212
134

61.3
38.7

828
153
62

79.4
14.7
5.9

263
53
18

78.7
15.9
5.4

296
46
21

81.5
12.7
5.8

269
54
23

77.8
15.6
6.7

576
467

55.2
44.8

191
143

57.2
42.8

211
152

58.1
41.9

174
172

50.3
49.7

953
64
15
11

91.4
6.1
1.4
1.1

307
19
3
5

91.9
5.7
0.9
1.5

333
22
7
1

91.7
6.1
1.9
0.3

313
23
5
5

90.5
6.7
1.5
1.5

630
341
54
18

60.4
32.7
5.2
1.7

197
112
22
3

59.0
33.5
6.6
0.9

236
108
14
5

65.0
29.8
3.9
1.4

197
121
18
10

56.9
35.0
5.2
2.9

P value

< .001

.673

.076

.570

.107

.815
790
253

75.7
24.3

252
82

75.5
24.6

279
84

76.9
23.1

259
87

74.9
25.1

248
198
270
324
3

23.8
19.0
25.9
31.1
0.3

72
68
78
113
3

21.6
20.4
23.4
33.8
0.9

94
58
99
112
0

25.9
16.0
27.3
30.9
0.0

82
72
93
99
0

23.7
20.8
26.9
28.6
0.0

242
236
273
292

23.2
22.6
26.2
28.0

78
79
90
87

23.4
23.7
27.0
26.1

92
84
90
97

25.3
23.1
24.8
26.7

73
73
93
108

20.8
21.1
26.9
31.2

576
467

55.2
44.8

166
168

49.7
50.3

195
168

53.7
46.3

215
131

62.1
37.9

355
392
296

34.0
37.6
28.4

112
126
96

33.5
37.7
28.7

118
150
95

32.5
41.3
26.2

125
116
105

36.1
33.5
30.4

378
188
477

36.2
18.0
45.7

130
47
157

38.9
14.1
47.0

130
57
176

35.8
15.7
48.5

118
84
144

34.1
24.3
41.6

367
676

35.2
64.8

102
232

30.5
69.5

113
250

31.1
68.9

152
194

43.9
56.1

.107

.612

.004*

.320

.005*

< .001*

Abbreviations: GTR = gross total resection; RT = radiation therapy; STR = subtotal resection; WHO = World Health Organization.
* Significant values with P < 0.05.

145 patients with intracranial ependymoma. The authors
reported a trend toward inferior local control in WHO
grade II patients after GTR/ (near total resection) with
RT initiation later than 9 weeks after surgery but did not

observe this in grade III patients.9 No such discrepancy
based on WHO grade was observed in this analysis.
The effect of RT timing on OS was previously evaluated in medulloblastoma using the NCDB. Chin and
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Figure 2 Overall survival curves as a function of postoperative radiation therapy timing in the primary analytical data set (n = 1043
patients). No significant difference in overall survival was observed as a function of radiation therapy timing.

Figure 3 Overall survival curves as a function of postoperative radiation therapy timing in patients treated between 2010 and 2016
(n = 565), when extent of surgical resection was known in all patients.

colleagues8 reported no clear effect on survival from
delaying RT up to 90 days after surgery. Of note, the
authors found that initiation of RT within 3 weeks of surgery was associated with inferior survival, although they

noted that this finding may have been explained by an
imbalance in adverse factors, such as presence of metastatic disease, in that group.8 Owing to concern regarding
neurocognitive deficits after craniospinal irradiation,
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Multivariate analysis for overall survival

Variable

Entire data set (n = 1043)
HR (95% CI)

Time to adjuvant RT (weeks)
<5
5-8
>8
WHO tumor grade
Grade II
Grade III
Tumor location
Infratentorial
Supratentorial
Unknown
Surgical resection
GTR
STR
Unknown
RT dose (Gy)
≤54
>54
Age
1-20
21-39
Race
White
Nonwhite
Unknown
Sex
Male
Female
Charlson Deyo score
0
1
2
3
Insurance status
Private
Medicaid/Medicare/govt.
Uninsured
Unknown
Residential distance to hospital (miles)
≤50
>50
Median income
1st quartile (lowest)
2nd quartile
3rd quartile
4th quartile (highest)
Unknown
Year of Diagnosis
2004-2006
2007-2009
2010-2012
2013-2015

P value

Subgroup (n = 565)
HR (95% CI)

P value

Reference
0.902 (0.623-1.305)
1.075 (0.739-1.563)

.583
.706

Reference
0.819 (0.445-1.507)
0.973 (0.545-1.736)

.521
.926

Reference
2.752 (1.969-3.846)

< .001*

Reference
4.296 (2.334-7.906)

< .001*

Reference
0.748 (0.509-1.098)
0.937 (0.639-1.376)

.138
.741

Reference
0.767 (0.415-1.420)
0.873 (0.450-1.694)

.399
.688

Reference
2.253 (1.405-3.611)
1.429 (0.958-2.131)

< .001*
.0810

Reference
2.267 (1.381-3.721)

.001*

Reference
1.040 (0.738-1.465)

.822

Reference
1.069 (0.610-1.875)

.815

Reference
0.880 (0.601-1.288)

.510

Reference
1.109 (0.632-1.946)

.718

Reference
0.423 (0.246-0.727)
0.762 (0.371-1.565)

.002
.458

Reference
0.465 (0.213-1.016)
0.592 (0.139-2.516)

.055
.477

Reference
0.813 (0.596-1.108)

.190

Reference
0.879 (0.536-1.443)

.611

Reference
1.157 (0.665-2.013)
0.915 (0.223-3.759)
1.242 (0.296-5.220)

.606
.902
.767

Reference
1.090 (0.424-2.801)
0.772 (0.101-5.886)
1.387 (0.177-10.892)

.859
.803
.756

Reference
1.064 (0.757-1.497)
1.402 (0.715-2.747)
2.408 (1.025-5.655)

.720
.325
.044

Reference
1.308 (0.761-2.248)
1.759 (0.684-4.523)
7.371 (1.935-28.075)

.331
.241
.003

Reference
0.759 (0.517-1.114)

.159

Reference
0.550 (0.282-1.073)

.080

Reference
1.200 (0.763-1.885)
0.842 (0.550-1.289)
0.703 (0.452-1.094)
3.332 (0.435-25.496)

.430
.430
.118
.246

Reference
1.324 (0.664-2.640)
0.788 (0.371-1.677)
0.880 (0.447-1.734)

.425
.537
.713

Reference
1.123 (0.752-1.677)
0.004 (0.000-0.039)
0.002 (0.000-0.025)

.570
< .001*
< .001*

Reference
0.586 (0.331-1.040)

.068

Abbreviations: CI = confidence interval; GTR = gross total resection; HR = hazard ratio; RT = radiation therapy; STR = subtotal resection;
WHO = World Health Organization.
* Significant values with P < 0.05.
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younger patients with medulloblastoma less commonly
receive RT than older patients. Kann and colleagues7
reported that deferral of RT in patients with medulloblastoma between 3 to 8 years of age was associated with significantly worse OS in the NCDB, affirming the
importance of RT on survival in this population.
Adjuvant RT is generally recommended after maximal
safe resection of grade II-III intracranial ependymoma.
The role of RT has also been questioned in selected populations, including children with grade II supratentorial
tumors after GTR and adults.10,11 Mature results from
ACNS 0831 will provide further information on the former group. The role of adjuvant RT is arguably more
controversial in adults. Prabhu and colleagues11 reported
no OS benefit with adjuvant RT in adults (≥22 years old)
who received RT. In that cohort, 80% of patients had
grade II tumors and two-thirds were supratentorial compared with 55.2% grade II and 37.6% supratentorial in
this study. We hypothesize that differences in the incidence of different molecular subtypes of ependymoma
between pediatric and adult patients may explain this
observed variation in tumor characteristics and potentially lead to the observed differences in survival between
manuscripts. In 2016, Ramaswamy and colleagues12
reported clinically significant OS differences for patients
with posterior fossa A and B (PFA and PFB) infratentorial tumors, and a clear benefit from adjuvant RT in PFA
tumors. The authors concluded that selected patients with
PFB tumors may safely be observed after GTR, but validation in a prospective trial is needed to definitively
address this hypothesis.
For many malignant pediatric and adult brain tumors,
postoperative RT regularly begins within 5 weeks of initial surgery to reduce the risk that any microscopic or
gross residual disease may repopulate after surgery.13
Delaying RT initiation, however, may provide several
competing benefits. For example, it may also enable time
for patients to undergo second look surgery to achieve
GTR or permit patients to complete inpatient physical
therapy when necessary. Finally, it may provide adequate
time to develop a high quality treatment plan or be
referred to a high volume pediatric RT center.
In this analysis, both STR and WHO grade III tumors
were significantly associated with inferior OS, consistent
with prior studies.14-16 Male gender was previously
reported as an adverse risk factor, but was not significant
in this analysis.15 Metastatic disease is another known
adverse prognostic factor, but such patients were
excluded from this analytical set. Of note, no dose
response was observed for patients receiving <54 Gy in
either the primary cohort or the subgroup analysis with
known extent of surgical resection. This finding is concordant with 2 recent reports9,17 but not with a recent
NCDB analysis. Ager and colleagues18 reported a dose
response for OS in children aged 2 to 18 treated with >54

RT time and survival in ependymoma
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Gy with no benefit from dose escalation observed in
adults and children <2 years old. After adjusting for significant prognostic factors in the MVA, delayed RT timing was not associated with an elevated HR for death in
this analysis.
Several limitations in our study must be acknowledged. First, selection and information biases are oftentimes inseparable from retrospective analyses and must
be considered when applying our results to clinical practice. Extent of resection was reported in only 54.3% of
the primary analytical cohort, which cannot be easily
overcome. Missing information can affect results in registry-based series, and data coding errors certainly exist
within large databases. A planned subset analysis demonstrated no clear difference in the survival estimates
observed in only the patients with known GTR/STR status. The completeness of the remaining available data
and this step helped to counter the possibility that the
observed effect was due to selection bias. Of note, the
role of adjuvant chemotherapy is still uncertain in pediatric ependymoma,3 but it may be elucidated by cooperative group trials.
In the NCDB, outcome measures were limited to OS;
data regarding local and distant failure and cancer-specific survival cannot be extracted. Although this is a
known limitation of NCDB analyses, the predominant
cause of mortality in children diagnosed with malignant
brain tumors is either related to the tumor or its treatment.
This is particularly true during early follow-up, with
competing risks of death rising in later years19 as the incidence of significant comorbidities related to curative
therapy increases.20,21 Although the NCDB provides adequate power to address hypotheses regarding RT timing,
duration of follow-up remains one limitation. Ependymoma can recur >5 years after diagnosis and treatment,
and long-term follow-up is important for this5 and other
pediatric brain tumors. We acknowledge that follow-up
was only 4.77 years in this study, and that delayed RT
may lead to an increased risk of local failure and a resulting effect on survival with longer follow-up than in this
data set. In addition, due to its granularity, large databases like the NCDB do not provide a clear explanation
for why particular treatments were selected, such as why
patients received delayed RT. For example, selected
patients who received delayed RT may have done so after
a second look surgery; this could potentially explain the
observed lack of difference in OS in this analysis as a
function of RT timing. We further recognize that observational studies cannot replace randomized data as the
standard for outcomes research, although registry data
can address important clinical questions not adequately
evaluated in randomized trials.
Molecular subtype information for ependymoma is not
included in the NCDB. This classification system is contemporary22 and evolving23,24 and has only recently been
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incorporated into routine testing. Of note, ACNS 0121
demonstrated no clear difference in event-free survival
between PFA and B infratentorial tumors or based on
RELA fusion status but did identify significantly inferior
event-free survival with 1q gain.4,15 In the future, molecular data should be regularly recorded in cooperative
group trials and large registries for ependymoma and
other brain tumors to better understand the effect of
molecular subtype on outcomes.
In summary, our NCDB analysis demonstrated no
clear survival effect with delayed RT in pediatric and
young adult patients with localized intracranial ependymoma. Selected patients, including those with metastatic
disease, may benefit from early RT administration. Given
the clear importance of GTR on survival, we advise complete surgical resection whenever feasible, even if second
look surgery is required, leading to a delay in adjuvant
RT. This approach is consistent with ACNS 0121 and
ACNS0831.15 Routine delays in postoperative RT should
be avoided, but these data suggest that it may be considered in selected patients who may benefit from second
look surgery, require additional time for adequate healing, or to facilitate referral to a high volume RT center.
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